|Day Low/High||22.91 / 23.42|
|52 Wk Low/High||4.35 / 20.65|
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Diagnostic firms can have an advantage of recurring revenue streams.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
Your questions are answered in our latest addition of the biotech mailbag.
Some good discussions today on the Daily Diary. Look forward to continuing the conversation tomorrow as we look to wrap up a solid week for equities. Market was lackluster today but had a ton of earnings reports to take into account. Not to mention ...
V-shaped moves are more common than they used to be.
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
The rapidly growing genetic testing concern is executing its growth plan marvelously.
Garvis Toler, head of global capital markets at the NYSE, reviews the landscape of IPOs during the first half of 2015 and previews what's in store for the second half.